Fibroblast Derived Human Engineered Connective Tissue for Screening Applications
August 20th, 2021
3.5K views
Presented here is a protocol to generate engineered connective tissues for a parallel culture of 48 tissues in a multi-well plate with double poles, suitable for mechanistic studies, disease modeling, and screening applications. The protocol is compatible with fibroblasts from different organs and species and is exemplified here with human primary cardiac fibroblasts.
Overview
This protocol allows fibroblasts to build and organize their own environment under defined mechanical conditions, resulting in anisotropic tissues that mimic the natural environment. It enables the comparison of up to 48 conditions in parallel and is adaptable to various cell types and culture conditions.
Key Study Components
Area of Science
- Connective tissue engineering
- Fibroblast biology
- Mechanistic studies
Background
- Fibroblasts play a crucial role in tissue structure and function.
- Understanding their behavior in engineered environments can inform disease modeling.
- Fibrotic diseases are a significant area of research due to their impact on health.
- Current methods often lack reproducibility and flexibility.
Purpose of Study
- To develop a reproducible protocol for generating engineered connective tissues.
- To facilitate mechanistic studies and drug screening for fibrotic diseases.
- To allow for the comparison of multiple experimental conditions simultaneously.
Methods Used
- Utilization of a multi-well plate with double poles for tissue culture.
- Application of defined mechanical conditions to fibroblasts.
- Incorporation of pro-fibrotic factors or antifibrotic drugs.
- Assessment of tissue stiffness and matrix composition.
Main Results
- Engineered tissues exhibited stiffness and matrix compositions similar to natural environments.
- The protocol demonstrated flexibility across different cell types.
- Reproducibility was confirmed across multiple laboratories.
- Insights into fibrotic disease mechanisms were gained through drug application.
Conclusions
- This protocol provides a valuable tool for studying fibrotic diseases.
- It enhances the ability to conduct parallel experiments under controlled conditions.
- The method's adaptability makes it suitable for various research applications.
Frequently Asked Questions
What types of cells can be used with this protocol?
The protocol is compatible with fibroblasts from different organs and species.
How many conditions can be tested simultaneously?
Up to 48 conditions can be compared in parallel.
What are the applications of this protocol?
It is suitable for mechanistic studies, disease modeling, and drug screening.
Can this method be reproduced in different laboratories?
Yes, the protocol is designed to be reproducible across laboratories.
What is the significance of anisotropic tissues?
Anisotropic tissues have directional properties that mimic natural tissue behavior.
How does this protocol contribute to fibrotic disease research?
It allows for the study of underlying processes and therapies for fibrotic diseases.
Executive Industry Relevance
This protocol enables reproducible generation of human-derived engineered connective tissues (ECT) in a 48-well format, providing a scalable 3D model for studying fibroblast behavior under defined biomechanical load. It supports mechanistic de-risking of antifibrotic targets by allowing parallel testing of pro-fibrotic factors and drug candidates, with quantitative readouts on tissue compaction, contraction, and stiffness. The system enhances predictive confidence in early discovery by modeling human-relevant tissue responses to pharmacological perturbations.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of fibroblast-to-myofibroblast transdifferentiation under controlled mechanical and biochemical conditions.
- Scientific Value: Supports functional validation of antifibrotic targets through dose-response analysis of compounds like Latrunculin A on tissue contraction and stiffness.
- Operational Value: Facilitates target de-risking by linking cytoskeletal mechanisms to tissue-level biomechanical outcomes in a human-relevant system.
Screening & Assay Development
- Scientific Value: Provides a standardized, high-throughput platform for screening compounds affecting tissue mechanics, with readouts on compaction, contraction, and elastic modulus.
- Operational Value: Enables parallel testing of up to 48 conditions per plate, supporting dose-response and time-course assays under consistent biomechanical loading.
- Operational Value: Uses defined, minimal components (collagen I, FGM, NaOH) to ensure reproducibility across laboratories and minimize batch variability.
Translational & Preclinical Research
- Scientific Value: Models human cardiac fibroblast responses in a 3D environment, improving translational relevance over 2D cultures for fibrosis mechanism studies.
- Scientific Value: Allows study of tissue-level phenotypes such as stiffness and extensibility, which correlate with pathological remodeling in fibrotic diseases.
- Operational Value: Supports longitudinal analysis of tissue dynamics over five days, enabling chronic compound exposure studies relevant to preclinical efficacy.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation to lead optimization, providing a human-relevant 3D assay for mechanism-of-action confirmation and phenotypic screening in fibrosis programs.
- Discovery Biology: Supports hypothesis testing of fibroblast-matrix interactions and pathway modulation under defined tensile load.
- Screening: Delivers quantitative, reproducible outputs (tissue diameter, contraction %, Young’s modulus) for hit validation and SAR progression.
- Analytics: Enables automated image-based analysis of tissue geometry and stress-strain profiling for objective, data-driven decision making.
- Translational Research: Bridges in vitro findings to pathophysiological relevance by measuring tissue stiffness and failure points analogous to fibrotic remodeling.
- Enterprise Reuse: The 48-well format and minimal reagent requirements allow integration into existing screening infrastructures with low adaptation cost.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by isolating cell-matrix contributions to tissue stiffening and contractility.
- Operational Value: Ensures assay reproducibility through standardized cell preparation, hydrogel mixing, and casting parameters.
- Strategic Value: Improves go/no-go decisions by providing early, human-predictive data on antifibrotic efficacy and target engagement.
- Portfolio Impact: Enables risk-adjusted prioritization of candidates based on dose-dependent effects on tissue mechanics and actin integrity.
Implementation Considerations
- Requires expertise in primary fibroblast culture, hydrogel handling, and sterile technique to ensure cell viability and matrix integrity.
- Dependent on access to a dynamic mechanical riometer with temperature-controlled bath and automated image analysis tools for biomechanical profiling.
- Necessitates standardization of cell seeding density (8.9 million cells/mL) and collagen neutralization across users to minimize variability in tissue formation.
- Adaptation to non-cardiac fibroblasts may require optimization of culture medium and loading conditions to reflect tissue-specific phenotypes.
- Limited to endpoints assessable via tissue geometry and tensile testing; molecular readouts require parallel sampling or fixation.
Biopharma FAQs
Why does measuring tissue compaction and contraction matter for target validation?
Tissue compaction and contraction reflect fibroblast-mediated matrix remodeling, which is driven by actin cytoskeleton integrity and serves as a functional readout of antifibrotic target engagement. Changes in these parameters under compound treatment indicate modulation of pathogenic fibroblast activity, enabling mechanistic de-risking before advancing to in vivo models.
How does isolating the independent variable (e.g., drug concentration) improve discovery pipeline efficiency?
By controlling variables such as cell density, collagen concentration, and mechanical load, the protocol ensures that observed differences in tissue mechanics are attributable to the independent variable, such as drug dose or genetic perturbation. This increases confidence in structure-activity relationships and reduces false positives in hit validation.
What quantitative dependent variable measurements enable predictive modeling of fibrotic responses?
The protocol generates quantitative endpoints including tissue diameter change (compaction), contraction percentage, Young’s modulus (stiffness), ultimate strain (extensibility), and toughness (energy to failure). These metrics allow correlation of pharmacological effects with tissue-level biomechanics, supporting predictive modeling of antifibrotic efficacy.
Why are replication requirements important for cross-functional collaboration in fibrosis programs?
Reproducibility across wells, plates, and laboratories ensures that data generated by discovery biology, screening, and preclinical teams are comparable and reliable. Standardized protocols reduce variability in tissue formation, enabling consistent interpretation of compound effects across functions and sites.
What statistical analysis capabilities are required before implementing this assay in a screening cascade?
Implementation requires the ability to normalize force by cross-sectional area, generate stress-strain curves, and calculate derived parameters such as slope of elastic region (Young’s modulus) and area under the curve (resilience, toughness). Software for automated image analysis and curve fitting is essential to ensure objective, high-throughput data extraction.
Chapters in this video
0:04
Introduction
0:52
Primary Cardiac Fibroblast Preparation
1:39
Enzymatic Dispersion of Human Cardiac Fibroblasts
2:52
Engineered Connective Tissue Preparation
5:28
Cross-Sectional Area Measurement to Assess ECT Compaction
5:55
Pole Deflection Analysis to Monitor ECT Contraction
6:32
Destructive Tensile Measurement and Stress-Strain Analysis to Assess ECT
8:20
Results: Effect of Actin Polymerization on ECT Compaction, Contraction, and Stiffness
9:22
Conclusion
